| Autor: |
Mokkarala S; 1 School of Medicine, University of California, Davis, Sacramento, CA, USA.; Current affiliation: Department of Obstetrics and Gynecology, Kaiser Permanente Los Angeles Medical Center., Johnson C; 2 Division of Gastroenterology and Hepatology, University of California, Davis, Sacramento, CA, USA., Sarkar S; 2 Division of Gastroenterology and Hepatology, University of California, Davis, Sacramento, CA, USA., Rudas RJ; 3 Mule Creek State Prison, California Department of Corrections and Rehabilitation, Ione, CA, USA. |
| Abstrakt: |
The burden of hepatitis C virus (HCV) infection is disproportionately high in U.S. federal and state prisons. This offers a unique opportunity for targeted HCV screening and treatment. New, highly effective, oral direct-acting antiviral (DAA) agents have the potential to eliminate many of the hurdles previously imposed by older interferon-based therapies. However, a relative deficit of providers motivated or empowered to treat HCV, along with a lack of treatment data on use of DAAs in prisons, greatly restricts the ability to treat the prison population. Here, we present a retrospective chart review of HCV treatment with DAAs by a family practitioner in a California state prison. Our data demonstrate that focused treatment by a primary care practitioner can achieve high HCV cure rates even in historically difficult to treat populations. Treatment of prison populations per local and national guidelines by family practitioners should be pursued to facilitate the eradication of hepatitis C in the United States. |
